ClinicalTrials.gov
public full text
Public Domain
Carbohydrate Antigen 19-9 in Colorectal Cancer
4,972 patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital were retrospectively reviewed. CA19-9 is a valuable prognostic and diagnostic marker for CRC when used adjunctively with CEA and can be a supplementary marker with CEA to improve sensitivity, especially with elevated preoperative CA19-9.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Diagnostic Performance of Platelet-to-Lymphocyte Ratio and CA19-9 Added to EUS-FNA for Solid Pancreatic Lesions: A Single-Center Retrospective Study.#615874
- Diagnostic value of combined serum CEA and CA19-9 in colorectal cancer A meta-analysis.#170759
- Significance of Cortactin Expression in Colorectal Adenocarcinomas#1161716
- A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)#801249
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease#1171717
Record · ID 1101939
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive